Akeso Inc. Shares Gain Over 5% as HARMONi-GI1 Study Results Debut at 2026 ESMO Congress

Stock News10-28

Akeso Inc. (09926) climbed more than 5%, rising 5.26% to HK$85.1 as of press time, with a turnover of HK$657 million.

On the news front, the company recently announced that HARMONi-GI1/AK112–309 was selected as a Late-Breaking Abstract (LBA) for an oral presentation at the Presidential Symposium of the 2026 ESMO Congress, presented by the principal investigator, Academician Zhou Jian, President of Zhongshan Hospital Affiliated to Fudan University.

HARMONi-GI1/AK112–309 (CTR20243164) is a randomized, controlled, double-blind, registrational Phase III clinical study evaluating ivonescimab combined with chemotherapy versus durvalumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer, enrolling a total of 682 subjects.

In August 2026, a pre-specified interim analysis assessed by the Independent Data Monitoring Committee (IDMC) showed that the HARMONi-GI1/AK112–309 study met its primary endpoint of overall survival (OS), achieving statistically significant and clinically meaningful positive results; the study also met all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).

The breakthrough data from the HARMONi-GI1 study strongly support the potential of ivonescimab combined with chemotherapy as a new standard first-line treatment for advanced biliary tract cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131553574?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-28 14:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131553574","market":"fut","top_or_hot":-1,"title":"Akeso Inc. Shares Gain Over 5% as HARMONi-GI1 Study Results Debut at 2026 ESMO Congress","media":"Stock News","content":"<p>Akeso Inc. (09926) climbed more than 5%, rising 5.26% to HK$85.1 as of press time, with a turnover of HK$657 million.<br><br>On the news front, the company recently announced that HARMONi-GI1/AK112–309 was selected as a Late-Breaking Abstract (LBA) for an oral presentation at the Presidential Symposium of the 2026 ESMO Congress, presented by the principal investigator, Academician Zhou Jian, President of Zhongshan Hospital Affiliated to Fudan University.<br><br>HARMONi-GI1/AK112–309 (CTR20243164) is a randomized, controlled, double-blind, registrational Phase III clinical study evaluating ivonescimab combined with chemotherapy versus durvalumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer, enrolling a total of 682 subjects.<br><br>In August 2026, a pre-specified interim analysis assessed by the Independent Data Monitoring Committee (IDMC) showed that the HARMONi-GI1/AK112–309 study met its primary endpoint of overall survival (OS), achieving statistically significant and clinically meaningful positive results; the study also met all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).<br><br>The breakthrough data from the HARMONi-GI1 study strongly support the potential of ivonescimab combined with chemotherapy as a new standard first-line treatment for advanced biliary tract cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akeso Inc. Shares Gain Over 5% as HARMONi-GI1 Study Results Debut at 2026 ESMO Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkeso Inc. Shares Gain Over 5% as HARMONi-GI1 Study Results Debut at 2026 ESMO Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-28 14:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Akeso Inc. (09926) climbed more than 5%, rising 5.26% to HK$85.1 as of press time, with a turnover of HK$657 million.<br><br>On the news front, the company recently announced that HARMONi-GI1/AK112–309 was selected as a Late-Breaking Abstract (LBA) for an oral presentation at the Presidential Symposium of the 2026 ESMO Congress, presented by the principal investigator, Academician Zhou Jian, President of Zhongshan Hospital Affiliated to Fudan University.<br><br>HARMONi-GI1/AK112–309 (CTR20243164) is a randomized, controlled, double-blind, registrational Phase III clinical study evaluating ivonescimab combined with chemotherapy versus durvalumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer, enrolling a total of 682 subjects.<br><br>In August 2026, a pre-specified interim analysis assessed by the Independent Data Monitoring Committee (IDMC) showed that the HARMONi-GI1/AK112–309 study met its primary endpoint of overall survival (OS), achieving statistically significant and clinically meaningful positive results; the study also met all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).<br><br>The breakthrough data from the HARMONi-GI1 study strongly support the potential of ivonescimab combined with chemotherapy as a new standard first-line treatment for advanced biliary tract cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348784397.USD","symbol_name":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1131553574","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131553574","pubTimestamp":1793167345,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Akeso Inc. (09926) climbed more than 5%, rising 5.26% to HK$85.1 as of press time, with a turnover of HK$657 million.On the news front, the company recently announced that HARMONi-GI1/AK112–309 was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","KCAI":"KraneShares China Alpha Index ETF","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1574":"生物医药B类股","09926":"康方生物","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","VXUS":"国际股票ETF-Vanguard","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","BK4588":"碎股","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","BK1161":"生物科技","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC"},"translate_title":"HARMONi-GI1 研究结果在 2026 年 ESMO 大会上首次亮相，Akeso Inc. 股价上涨超过 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1,"KURE":1,"KCAI":1,"VXUS":1},"content_text":"Akeso Inc. (09926) climbed more than 5%, rising 5.26% to HK$85.1 as of press time, with a turnover of HK$657 million.On the news front, the company recently announced that HARMONi-GI1/AK112–309 was selected as a Late-Breaking Abstract (LBA) for an oral presentation at the Presidential Symposium of the 2026 ESMO Congress, presented by the principal investigator, Academician Zhou Jian, President of Zhongshan Hospital Affiliated to Fudan University.HARMONi-GI1/AK112–309 (CTR20243164) is a randomized, controlled, double-blind, registrational Phase III clinical study evaluating ivonescimab combined with chemotherapy versus durvalumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer, enrolling a total of 682 subjects.In August 2026, a pre-specified interim analysis assessed by the Independent Data Monitoring Committee (IDMC) showed that the HARMONi-GI1/AK112–309 study met its primary endpoint of overall survival (OS), achieving statistically significant and clinically meaningful positive results; the study also met all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).The breakthrough data from the HARMONi-GI1 study strongly support the potential of ivonescimab combined with chemotherapy as a new standard first-line treatment for advanced biliary tract cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131553574","isCrawlerRequest":true}